Patents Assigned to INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
  • Publication number: 20210177755
    Abstract: The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.
    Type: Application
    Filed: October 30, 2018
    Publication date: June 17, 2021
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Léon Bérard
    Inventors: Charles DUMONTET, Abdelkamel CHETTAB
  • Patent number: 11021689
    Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: c1) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV e
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 1, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTER, CHU NANTES, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
    Inventor: Nicole Brument
  • Patent number: 11000521
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: May 11, 2021
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Patent number: 11001634
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 11, 2021
    Assignees: GAMAMABS PHARMA, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
  • Patent number: 10995089
    Abstract: The present invention concerns a compound of formula (I): H or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 4, 2021
    Assignees: AGV DISCOVERY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE MONTPELLIER
    Inventors: Jean-François Guichou, Cédric Bories, Clément Geoffroy, Charline Duquenne, Muriel Gelin, Gilles Labesse, Yannick Bessin, Loic Mathieu
  • Patent number: 10980873
    Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 20, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES
    Inventors: Frédéric Tangy, Marc Gregoire, Jean-François Fonteneau, Jean-Baptiste Guillerme, Chantal Combredet
  • Patent number: 10968253
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 6, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
  • Patent number: 10966940
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: April 6, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Auris Medical AG
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Patent number: 10968422
    Abstract: A device for treating at least one biological cell includes at least one treatment support comprising a receiving surface enabling the adhesion of the at least one biological cell, at least one actuator capable of deforming said support in order to apply a stress to said at least one cell, and means of controlling said at least one actuator such that the actuator deforms the treatment support according to a given amplitude of deformation and for a given duration so as to generate at least one transitory pore in a membrane of the biological cell.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: April 6, 2021
    Assignees: Commissariat A L'Energie Atomique et aux Energies Alternatives, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Fabrice Casset, Arnaud Millet
  • Patent number: 10961219
    Abstract: The present invention relates to a compound of formula (I) wherein P1, P3, P4 and P5 are amino acid residues. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It also concerns the use of a compound of formula (I) as activity base probe to selectively detect Caspase-2 activity.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: March 30, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT-PARIS 7
    Inventor: Etienne Jacotot
  • Publication number: 20210088483
    Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the m
    Type: Application
    Filed: February 21, 2019
    Publication date: March 25, 2021
    Applicants: Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite De Paris, Ecole Nationale Superieure de Chimie de Paris
    Inventors: Hugo Salmon, Rabah Gahoual, Nathalie Mignet, Pascal Houze
  • Patent number: 10947323
    Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: March 16, 2021
    Assignees: Sorbonne Universite, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale (INSERM), Assistance Publique—Hopitaux De Paris, Université De Paris
    Inventors: Matthieu Sollogoub, Vincent Calvez, Anne-Geneviève Marcelin, Laurent Bouteiller, Mickaël Menand, Pierre Evenou, Adélie Gothland, Dmitri Colesnic, Julien Rossignol
  • Patent number: 10947260
    Abstract: A compound of following formula (I): where: X is O or S; A is an aromatic (hetero)cycle having 5 to 10 atoms selected from among carbon and nitrogen atoms, optionally being substituted; R? is H or (C1-C6)alkyl group; R1, R2, R3, R4 and R5, the same or different, are selected from the group formed by: H, (C1-C6)alkyl groups and (C6-C10)aryl groups. The compound is for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 16, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE PRATIQUE DES HAUTES ETUDES, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Tangui Maurice, Jean-Noël Volle, David Virieux, Jean-Luc Pirat, Coralie Laborde
  • Patent number: 10941448
    Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 9, 2021
    Assignees: The Universite Paris-Saclay, The Assistance Publique-Hopitaux de Paris (APHP), The Institut National de la Sante et de la Recherche Medicale (INSERM), PML Screening, LLC
    Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
  • Patent number: 10925951
    Abstract: The present invention concerns a composition comprising at least one prophylactically or therapeutically active agent selected from the group consisting of attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a c DNA from Porphyromonas gingivalis, for use as a vaccine for preventing or treating periodontitis, diabetes, obesity and/or complications thereof in a subject. The present invention also concerns an isolated antibody having specificity for Porphyromonas gingivalis for use for preventing or treating periodontitis, diabetes, obesity and/or complications thereof in a subject.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 23, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventors: Vincent Blasco-Baque, Lucile Garidou, Rémy Burcelin
  • Patent number: 10912568
    Abstract: The balloon includes a pouch formed of a sealed wall delimiting an internal space, and a valve for filling the internal space with a fluid, capable of being occluded after filling the internal space. The pouch delimits a fluid-draining orifice opening into the internal space. The balloon further includes an occluding ball that occludes the draining orifice. The occluding ball can be spherical or polyhedral, and be capable of releasing the draining orifice under the effect of a magnetic field, so as to enable the at least partial drainage of the fluid contained in the internal space. The occluding ball is movable along at least two distinct axes in relation to the pouch.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 9, 2021
    Assignees: UNIVERSITÉ DE STRASBOURG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HÔPITAUX UNIVERSITAIRES DE STRASBOURG (HUS), INSTITUT HOSPITALO-UNIVERSITAIRE DE STRASBOURG, INSTITUT DE RECHERCHE CONTRE LES CANCERS DE L'APPAREIL DIGESTIF, BS MEDICAL TECH INDUSTRY
    Inventors: Nicolas Sananes, Romain Favre, Joël Leroy, Christian Debry, Christian Goetz, Bruno Mutet, Juan Hernandez, Bertrand Basch, Raymond Basch
  • Patent number: 10888592
    Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of Hafnia alvei.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: January 12, 2021
    Assignees: TARGEDYS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Romain Legrand, Nicolas Lucas
  • Publication number: 20210002607
    Abstract: The disclosure pertains to a defined cell culture medium for the expansion of human retinal progenitors, comprising or consisting of a nutrient medium, a SHH-pathway activator and a GSK3 inhibitor. To the use of the defined cell culture medium for the expansion of retinal progenitors, as well as to an in vitro method for expanding retinal progenitors, comprising: (i) placing a culture of human retinal progenitors in a defined cell culture medium as defined in claims 1 to 8; and (ii) culturing the cells in said defined cell culture medium.
    Type: Application
    Filed: March 6, 2019
    Publication date: January 7, 2021
    Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Sacha Reichman, Olivier Goureau, José-Alain Sahel
  • Patent number: 10881380
    Abstract: The present invention concerns a method for obtaining a functional parameter of a muscle having a part, the method comprising the steps of: a) applying ultrasound waves to the muscle, b) collecting the ultrasound waves retrodiffused by the muscle at a plurality of times, to obtain collected ultrasound waves, c) determining a first plurality of values representative of stiffness values of one part at a first plurality of times by using the collected ultrasound waves, d) determining a second plurality of values representative of deformation values of said part at a second plurality of times by using the collected ultrasound waves, and e) deducing at least one functional parameter based on the first plurality of values and the second plurality of values. The invention also concerns a corresponding device.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: January 5, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE PARIS DIDEROT—PARIS 7, ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Mickael Tanter, Mathieu Pernot
  • Patent number: 10875322
    Abstract: A device for deposition of particles on a target from a transparent slide having a film formed by a fluid containing suspended particles, by locally exciting the film using a laser, includes means for observing the local excitation region. The observation means comprise a sensor and a light source, the optical axes of which are substantially shared in a space between an optical splitter and the film. The optical beam of the imaging system and the optical beam of the laser are coaxially arranged in the space between the controlled optical deflection means and the film. The device comprises a first focusing optical unit arranged between the controlled optical deflection means and the film. The device comprises a second image-combining optical unit positioned between the sensor and the splitter, the sensor being positioned in the focal plane of the second optical unit.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: December 29, 2020
    Assignees: Universite de Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Bertrand Viellerobe, Romain Vaucelle, Fabien Guillemot